​

Halozyme Therapeutics Ownership | Who Owns Halozyme Therapeutics?

OverviewForecastRevenueFinancialsChartTranscripts

Halozyme Therapeutics Ownership Summary

Halozyme Therapeutics is owned by 48.55% institutional investors, 1.15% insiders, and 50.30% retail investors. Dld asset management, lp is the largest institutional shareholder, holding 24.72% of HALO shares. iShares Core S&P Mid-Cap ETF is the top mutual fund, with 3.43% of its assets in Halozyme Therapeutics shares.

HALO Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockHalozyme Therapeutics48.55%1.15%50.30%
SectorHealthcare Stocks 41.89%10.80%47.31%
IndustryBiotech Stocks 43.99%10.76%45.25%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Dld asset management, lp30.00M24.72%$42.34B
Blackrock17.62M13.88%$922.58M
Blackrock funding, inc. /de12.86M10.60%$943.17M
Vanguard group11.63M9.58%$852.93M
State street5.02M4.14%$368.11M
Arrowstreet capital, limited partnership3.29M2.71%$241.34M
Invesco3.25M2.67%$238.04M
Ubs group2.95M2.43%$216.04M
Snyder capital management l p2.73M2.25%$200.50M
Geode capital management2.43M2.00%$178.34M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Koa wealth management86.64K4.71%$6.35M
Snyder capital management l p2.73M3.79%$200.50M
Cutter capital management, lp120.00K3.33%$7.66M
Dld asset management, lp30.00M3.04%$42.34B
Panoramic capital89.43K2.95%$6.56M
Steamboat capital partners142.58K2.72%$10.46M
2xideas158.82K2.46%$11.65M
Bernzott capital advisors69.25K2.40%$5.08M
South street advisors247.85K2.38%$18.18M
Future fund62.45K1.62%$4.58M

Top Buyers

HolderShares% AssetsChange
Dld asset management, lp30.00M3.04%17.50M
Ubs group2.95M0.03%1.42M
Norges bank1.26M0.01%1.26M
Federated hermes1.45M0.19%1.08M
Voloridge investment management1.06M0.26%1.06M

Top Sellers

HolderShares% AssetsChange
Frontier capital management---1.27M
State street5.02M0.01%-915.84K
Artisan partners limited partnership62.59K0.01%-752.15K
Goldman sachs group684.52K0.01%-683.18K
Snyder capital management l p2.73M3.79%-663.85K

New Positions

HolderShares% AssetsChangeValue
Norges bank1.26M0.01%1.26M$60.05M
Voloridge investment management1.06M0.26%1.06M$77.59M
Bridgewater associates, lp487.08K0.14%487.08K$35.72M
Renaissance group478.74K1.32%478.74K$35.11M
M&g160.44K0.06%160.44K$11.71M

Sold Out

HolderChange
Total investment management-1.00
Harbor investment advisory-4.00
Raleigh capital management-6.00
Van hulzen asset management-8.00
Southstate-9.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 2025351-37.21%58,910,289-54.67%480.42%159-40.67%146-31.78%
Jun 30, 2025552-1.08%129,712,8686.64%1061.10%263-16.51%21229.27%
Mar 31, 202515-97.10%5,085,362-95.89%40.04%6-97.75%4-97.75%
Dec 31, 2024292-43.41%70,690,093-43.61%550.57%130-52.38%114-30.91%
Sep 30, 20245109.68%124,779,1382.05%981.06%27011.57%1653.77%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
iShares Core S&P Mid-Cap ETF4.01M3.43%-
Vanguard Total Stock Mkt Idx Inv3.87M3.31%-94.98K
Vanguard US Total Market Shares ETF4.03M3.27%3.36K
Vanguard Small Cap Index2.99M2.56%-20.32K
iShares Russell 2000 ETF3.13M2.54%-
Aviva Investors GlConvtAbsRet I USD Acc2.74M2.16%2.74M
SPDR® S&P Biotech ETF2.18M1.86%4.86K
Vanguard Small Cap Growth Index Inv1.69M1.44%-1.74K
Delaware Small Cap Core I1.74M1.37%-10.77K
Vanguard Institutional Extnd Mkt Idx Tr1.32M1.13%-572.80K

Recent Insider Transactions

DateNameRoleActivityValue
Nov 12, 2025Torley Helen PRESIDENT AND CEOSell$893.03K
Nov 12, 2025Torley Helen PRESIDENT AND CEOSell$482.27K
Nov 11, 2025Torley Helen PRESIDENT AND CEOSell$305.51K
Nov 11, 2025Torley Helen PRESIDENT AND CEOSell$275.18K
Nov 10, 2025Torley Helen PRESIDENT AND CEOSell$1.37M

Insider Transactions Trends

DateBuySell
2027 Q1--
2026 Q1--
2025 Q4-13
2025 Q3-27
2025 Q2-7

HALO Ownership FAQ

Who Owns Halozyme Therapeutics?

Halozyme Therapeutics shareholders are primarily institutional investors at 48.55%, followed by 1.15% insiders and 50.30% retail investors. The average institutional ownership in Halozyme Therapeutics's industry, Biotech Stocks , is 43.99%, which Halozyme Therapeutics exceeds.

Who owns the most shares of Halozyme Therapeutics?

Halozyme Therapeutics’s largest shareholders are Dld asset management, lp (30M shares, 24.72%), Blackrock (17.62M shares, 13.88%), and Blackrock funding, inc. /de (12.86M shares, 10.60%). Together, they hold 49.20% of Halozyme Therapeutics’s total shares outstanding.

Does Blackrock own Halozyme Therapeutics?

Yes, BlackRock owns 13.88% of Halozyme Therapeutics, totaling 17.62M shares as of Jun 2024. This represents 0.02% of BlackRock's total assets, with a market value of 922.58M$. In the last quarter, BlackRock decreased its holdings by -622K shares, a -3.41% change.

Who is Halozyme Therapeutics’s biggest shareholder by percentage of total assets invested?

Koa wealth management is Halozyme Therapeutics’s biggest shareholder by percentage of total assets invested, with 4.71% of its assets in 86.64K Halozyme Therapeutics shares, valued at 6.35M$.

Who is the top mutual fund holder of Halozyme Therapeutics shares?

iShares Core S&P Mid-Cap ETF is the top mutual fund holder of Halozyme Therapeutics shares, with 3.43% of its total shares outstanding invested in 4.01M Halozyme Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools